Exelixis

NASDAQ: EXEL
$22.36
-$0.45 (-2.0%)
Closing price August 7, 2020
Thursday's top analyst upgrades and downgrades included Adobe, Baker Hughes, Best Buy, Cisco Systems, CyberArk Software, Enphase Energy, Grubhub, Jumia Technologies, SmileDirectClub, Under Armour and...
Exelixis stock jumped early on Monday after the company, in conjunction with Bristol-Myers Squibb, announced positive late-stage results from its kidney cancer study.
The top analyst upgrades, downgrades and initiations seen on Monday included Chipotle Mexican Grill, Delphi Technologies, Dollar General, Facebook, Ingersoll-Rand, Nike, Okta and Quest Diagnostics.
The top analyst upgrades, downgrades and initiations seen on Friday included Biogen, Broadcom, Citigroup, Equifax, Fitbit, Intel, Kraft Heinz, Merck, Roku, Under Armour, United Technologies and...
The biotech team at SunTrust feel that it would not be a major surprise to see these six top companies post quarterly results that beat top-line Wall Street expectations.
Sears, Weyerhaeuser, Laredo Petroleum, and Exelixis were among the stocks posting new 52-week lows Monday.
Exelixis shares dipped on Monday after the company announced that it has initiated a late-stage trial in patients with radioiodine-refractory differentiated thyroid cancer (DTC).
JD.com, Turquoise Hills, Exelixis, and Floor & Decor Holdings all posted new 52-week lows Monday.
Invesco, Tal Education, Chemours, and Exelixis all posted new 52-week lows on Thursday.
SeaChange, Sears, Exelixis, and Adamis Pharma all posted new 52-week lows Tuesday.
Lannett Co., Scorpio Tankers, Mobile Telesystems, and Exelixis all posted new 52-week lows Monday.
These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed exceed first-quarter expectations.
The include Albermarle, Best Buy, Chipotle Mexican Grill, Exact Sciences, Fitbit, Itron, NuVasive, Palo Alto Networks and Stryker.
Shares of Exelixis slipped on Wednesday after the company reported results from its late-stage trial of cabozantinib for advanced hepatocellular carcinoma.
Exelixis saw its shares make a handy gain on Wednesday after the company received the nod from the FDA for Cabometyx tablets.